Drugs and Devices in the Clinical Management of Obesity Worldwide

Share Article

As the growing worldwide problem of obesity becomes more evident, including its commensurate healthcare costs, there is a coinciding proliferation of the number and type of approaches to address the problem.

Technologies for the management of obesity span surgical approaches, medical supervised severely restricted diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches. MedMarket Diligence maintains a focus on ongoing developments with it coverage of obesity and has completed a 2007 analysis on the worldwide market for products in the management of obesity.

"The recent decision by Sanofi-Aventis to withdraw its FDA application for the anti-obesity drug rimonabant, marketed as Acomplia, highlights the need for an effective pharmaceutical treatment for obesity," says Patrick Driscoll, President of MedMarket Diligence. "While developers in the market for device and other products to treat clinical obesity are working aggressively, it is clear that an effective pharmaceutical treatment will hold tremendous potential to compete with all treatment types."

The obesity treatment market worldwide is set to grow enormously, and will reach 6.4 billion by 2015. This includes prescription drugs for weight loss and maintenance; devices used in bariatric surgery and follow-up; and the predicted sales of drugs and devices with anticipated launch dates through 2015

The MedMarket Diligence report on the "Worldwide Market for the Clinical Management of Obesity" describes the clinical trends in the management of the obese, the products on the market and the status of those in development for bariatric surgery, drug therapy, gastric stimulation devices, brain stimulation devices, combination therapies and genetic therapy. The report provides a current and forecast market for these products in the U.S., Europe and Rest of World, and profiles key companies in the market, detailing the current products, products in development, market position and overall businesses in obesity management.

The report is described, with preliminary table of contents, at http://www.mediligence.com/rpt/rpt-s825.htm.

The report can be purchased direclty at https://www.mediligence.com/store/page22.html.

For additional information, contact Patrick Driscoll, at (949) 859-3401, or patrick mediligence com.

About MedMarket Diligence
MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries. The company publishes the MedMarkets newsletter, a monthly analysis of the market implications of new medical technologies, dedicated Reports on technology markets and the Medtech Startups Database.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Patrick Driscoll
Visit website